Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation

NCT04376944 | Unknown

• 1 other identifier: RECHMPL20_0261
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Use lay language. The Covid-19 pandemic hit France in March 2020 and stage 3 of the epidemic justified the introduction of national and unprecedented containment measures from March 17, 2020. The Montpellier CHU experienced peak hospitalizations of Covid-19 infections in late March. The estimate of the proportion of infected people in Occitania, South of France, for the 11th of May 2020 is 3.1% (95% CI: 1.9-5.9) for the Occitania region, to which Montpellier belongs. In the context of the Covid-19 epidemic, notably due to the absence of pharmacological or vaccine prophylaxis, barrier measures were of crucial importance, especially for exposed caregivers. These measures include an adaptation of individual behavior, the creation of a so-called "Covid" hospital, the wearing of specific equipment in all departments, the use in the rooms of Covid-19 patients of a gown, an apron, gloves, and a FFP2 type mask in the event of contact and sampling, protocolized and standardized bio-cleaning measures, a reorganization of the premises and the definition of specific circuits. In view of the second wave of the epidemic, estimating the effectiveness of the barrier measures is of major importance. The investigators therefore propose an evaluation of the effectiveness of these measures, by comparing the serological prevalence of infection among caregivers working directly in COVID units compared to caregivers working in services excluding the management of Covid-19 patients. Systematic evaluation in COVID-19 units of Sarc-Co-V2 infection will also be assessed, with naso-pharyngeal swabs.

Conditions

Caregivers; COVID-19

Keywords

barrier measures

Outcome Measures

Primary Outcomes (1)

• Proportion of caregivers and agents with a positive serodiagnosis

  Proportion of caregivers and agents with a positive serodiagnosis in COVID units versus non-COVID units

  1 day

Secondary Outcomes (1)

• Proportion of caregivers and agents with a positive RT-PCR

  1 day

Study Arms (2)

Exposed group

Caregivers and agents working directly in COVID units compared to those living.

Other: Survey

Control group

caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection

Other: Survey

Interventions

Survey OTHER

questionnaire on their symptoms and their exposures

Control group; Exposed group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

carers of the UH Montpellier

You may qualify if:

• exposed group: exposed caregivers and agents who worked in COVID units (medicine, resuscitation, screening) until their date of collection. An exposed agent or caregiver is defined by the entrance of rooms with a COVID-19 infection during their professional activity.
• low or unexposed group: caregivers or agents who have worked in non-COVID units in a non-COVID hospital

You may not qualify if:

• \- refusal to participate

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uh Montpellier

Montpellier, 34295, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

NC

MeSH Terms

Conditions

COVID-19

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Marie Bistoquet, MD

  University Hospital, Montpellier

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Alain MAKINSON, MCU-PH

CONTACT

0663075260; a-makinson@chu-montpellier.fr

Marie Bistoquet, MD

CONTACT

m-bistoquet@chu-montpellier.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2020
• First Posted: May 6, 2020
• Study Start: April 1, 2020
• Primary Completion: December 1, 2020
• Study Completion: December 30, 2020
• Last Updated: May 6, 2020

Record last verified: 2020-05

Locations

FR (1)